Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2370)	4/15/2005 1:39:09 PM
From: Extra Pale	Respond to of 3044

Found this interesting: (from trisenox phase 2) <In addition, seven out of 10 patients who had failed bortezomib therapy responded and 10 out of 16 patients who had received prior melphalan therapy responded.> Note that trisenox claims similar response rate to bortezomib in heavily pre-treated patients. TRISENOX Combination Regimen Induces High Rate of Responses in Patients With Late-stage, Relapsed or Refractory Multiple Myeloma Monday April 11, 7:00 am ET - Objective Responses Observed in 59 Percent of Evaluable Patients Including Many Refractory to Nearly All Other Major Classes of Therapeutics SEATTLE, April 11 /PRNewswire-FirstCall/ -- At the 10th International Myeloma Workshop, James Berenson, M.D., Medical & Scientific Director of the Institute for Myeloma & Bone Cancer Research presented data from a multicenter, phase II trial of a TRISENOX combination regimen, known as MAC (melphalan, TRISENOX and vitamin C), in relapsed or refractory multiple myeloma patients. The data showed that 22 of the 37 patients evaluated (60 percent) achieved an objective response, with eight patients experiencing a decrease in serum M-protein of 50 percent or more and 14 patients experiencing a decrease in serum M-protein of between 25 to 49 percent. Of the twenty-nine patients who had failed prior thalidomide or lenolinamide therapy, 14 patients responded to the TRISENOX regimen. In addition, seven out of 10 patients who had failed bortezomib therapy responded and 10 out of 16 patients who had received prior melphalan therapy responded. The regimen was well tolerated.